EUVIMEDEUVIMED entdecken
Crossref

Outcomes in Patients With Mitral Annular Disjunction and an Implantable‐Cardioverter Defibrillator

Fatima M Ezzeddine iD, Jee Won Jennifer Shin, Konstantinos C Siontis iD, Ammar M Killu iD, John Giudicessi iD, Michael J Ackerman iD, Abhishek J Deshmukh iD, Gurukripa N Kowlgi iD, Malini Madhavan iD, Christopher J McLeod, Samuel J Asirvatham iD, Freddy Del-Carpio Munoz iD

Journal of Cardiovascular Electrophysiology · 2025

DOI: 10.1111/jce.16612 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Cardiovascular Electrophysiology, 2025. Verfasst von Fatima M Ezzeddine und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota, USA. Hauptthemen laut MEDLINE: Defibrillators, Implantable, Mitral Valve, Electric Countershock, Death, Sudden, Cardiac. Die Arbeit nennt 21 Literaturangaben. Gefördert von: The authors received no specific funding for this work..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Mitral annular disjunction (MAD) carries an increased risk of complex ventricular arrhythmias, which can lead to sudden cardiac death. Many of these patients undergo implantable cardioverter defibrillator (ICD) implantation, but their ICD outcomes are not known.

Objective

The aim of this study was to assess the outcomes of ICD implantation and the predictors of appropriate ICD therapies in patients with MAD.

Methods

The study included patients with MAD who underwent ICD implantation. Clinical, electrocardiographic, cardiac imaging, and device therapy data were collected.

Results

Forty‐nine patients with MAD and ICD were included. Median age was 49 (21) years, and 29 (59%) were female. 13 (27%) patients underwent ICD implantation for primary prevention and 36 (73%) patients for secondary prevention. Over a median follow‐up of 27.3 (35.3) months, 23 (47%) patients received ICD therapies. 18 (37%) patients had appropriate ICD therapies, and 5 (10%) patients had inappropriate ICD shocks. Median time to first appropriate therapy was 22.3 (63.3) months. In patients with a secondary prevention ICD indication, the rate of appropriate ICD therapies was 44%, while in patients with a primary prevention ICD indication, it was 15%. Among patients with appropriate ICD therapies, the first therapies were delivered for monomorphic ventricular tachycardia (VT) in 7 (39%) patients and polymorphic VT or ventricular fibrillation (VF) in 11 (61%) patients. Patients with appropriate ICD therapies were more likely to have a history of SCA ( p = 0.003) and/or low left ventricular ejection fraction (LVEF) ( p = 0.022) before ICD implantation as compared to patients without appropriate ICD therapies.

Conclusions

In our cohort of patients with MAD and ICD, appropriate ICD therapies were common. Most appropriate ICD therapies were delivered for polymorphic VT or VF. Larger studies are needed to elucidate the mechanisms of VAs and refine risk stratification in MAD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Defibrillators, ImplantableMitral ValveElectric CountershockDeath, Sudden, CardiacPrimary PreventionTachycardia, VentricularHeart Valve DiseasesHumansFemaleMaleMiddle AgedTreatment OutcomeRisk FactorsTime FactorsAdultRetrospective StudiesSecondary PreventionAged

Stichwörter der Autor:innen

ICD dischargedefibrillatormitral annular disjunctionmitral valvemitral valve prolapseventricular arrhythmia

Autor:innen und Institutionen

  • Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota, USA.
  • Mayo Clinic Alix School of Medicine, Rochester, Minnesota, USA.
  • Department of Cardiovascular Medicine, Mayo Clinic, Jacksonville, Florida, USA.
  • Department of Pediatric and Adolescent Medicine, Mayo Clinic College of Medicine, Rochester, Minnesota, USA.
  • Department of Biomedical Engineering, Mayo Clinic, Rochester, Minnesota, USA.
  • Department of Clinical Anatomy, Mayo Clinic, Rochester, Minnesota, USA.

ORCID-Profile: Fatima M Ezzeddine, Konstantinos C Siontis, Ammar M Killu, John Giudicessi, Michael J Ackerman, Abhishek J Deshmukh, Gurukripa N Kowlgi, Malini Madhavan, Samuel J Asirvatham, Freddy Del-Carpio Munoz

Förderung

  • The authors received no specific funding for this work.

Zitieren

APA

Ezzeddine, F. M., Shin, J. W. J., Siontis, K. C., Killu, A. M., Giudicessi, J., Ackerman, M. J., Deshmukh, A. J., Kowlgi, G. N., Madhavan, M., McLeod, C. J., Asirvatham, S. J., & Munoz, F. D. (2025). Outcomes in Patients With Mitral Annular Disjunction and an Implantable‐Cardioverter Defibrillator. Journal of Cardiovascular Electrophysiology. https://doi.org/10.1111/jce.16612

Vancouver

Ezzeddine FM, Shin JWJ, Siontis KC, Killu AM, Giudicessi J, Ackerman MJ, et al. Outcomes in Patients With Mitral Annular Disjunction and an Implantable‐Cardioverter Defibrillator. Journal of Cardiovascular Electrophysiology. 2025. doi:10.1111/jce.16612

BibTeX
@article{Ezzeddine2025,
  author = {Ezzeddine, Fatima M and Shin, Jee Won Jennifer and Siontis, Konstantinos C and Killu, Ammar M and Giudicessi, John and Ackerman, Michael J and Deshmukh, Abhishek J and Kowlgi, Gurukripa N and Madhavan, Malini and McLeod, Christopher J and Asirvatham, Samuel J and Munoz, Freddy Del-Carpio},
  title = {Outcomes in Patients With Mitral Annular Disjunction and an Implantable‐Cardioverter Defibrillator},
  journal = {Journal of Cardiovascular Electrophysiology},
  year = {2025},
  doi = {10.1111/jce.16612}
}
Kostenlos starten →